{
  "drug_name": "Ceftriaxone",
  "drug_id": "ceftriaxone",
  "generic_name": "ceftriaxone",
  "brand_names": ["Rocephin"],
  "class": "Cephalosporin (3rd generation)",
  "version": "3.0.0",
  "last_updated": "2025-10-08",

  "routes": ["IV", "IM"],
  "default_route": "IV",

  "contraindications": {
    "absolute": [
      "severe_pcn_allergy_with_anaphylaxis",
      "severe_pcn_allergy_with_sjs",
      "severe_pcn_allergy_with_dress"
    ],
    "relative": [],
    "note": "SAFE for mild PCN allergy (rash only). Cross-reactivity <1%."
  },

  "allergy_considerations": {
    "mild_pcn_allergy": {
      "safe": true,
      "note": "Cephalosporins safe with PCN rash-only allergy. Cross-reactivity <1% per IDSA."
    },
    "severe_pcn_allergy": {
      "safe": false,
      "contraindicated": true,
      "note": "Avoid in anaphylaxis, SJS, DRESS. Use aztreonam instead."
    }
  },

  "pregnancy_category": "B",
  "pregnancy_safe": true,
  "pregnancy_notes": "Safe in all trimesters. Preferred agent for pyelonephritis in pregnancy.",

  "renal_adjustment": {
    "required": false,
    "note": "No dose adjustment needed for renal impairment. Primarily hepatic clearance."
  },

  "dosing": {
    "by_indication": {
      "pyelonephritis": {
        "dose": "1 g IV",
        "frequency": "q24h",
        "duration": "7-14 days",
        "note": "First-line IV therapy for community-acquired pyelonephritis",
        "route": "IV",
        "loading_dose": null
      },
      "pneumonia_cap": {
        "dose": "1-2 g IV",
        "frequency": "q24h",
        "duration": "5-7 days",
        "note": "Standard dose for community-acquired pneumonia",
        "route": "IV"
      },
      "meningitis": {
        "dose": "2 g IV",
        "frequency": "q12h",
        "duration": "10-14 days",
        "note": "HIGHER DOSE for CNS penetration in meningitis",
        "route": "IV",
        "loading_dose": null,
        "critical_note": "Meningitis requires q12h dosing, NOT q24h"
      },
      "bacteremia": {
        "dose": "2 g IV",
        "frequency": "q24h",
        "duration": "Varies by source",
        "route": "IV"
      },
      "intra_abdominal": {
        "dose": "1-2 g IV",
        "frequency": "q24h",
        "note": "Often combined with metronidazole for anaerobic coverage",
        "route": "IV"
      },
      "hap": {
        "dose": "2 g IV",
        "frequency": "q24h",
        "duration": "7-14 days",
        "note": "Hospital-acquired pneumonia - consider MRSA coverage",
        "route": "IV"
      },
      "vap": {
        "dose": "2 g IV",
        "frequency": "q24h",
        "duration": "7-14 days",
        "note": "Ventilator-associated pneumonia - often needs anti-pseudomonal coverage",
        "route": "IV"
      }
    },
    "pediatric": {
      "note": "50-100 mg/kg/day divided q12-24h (max 2-4 g/day depending on indication)"
    }
  },

  "monitoring": {
    "required": ["clinical response", "resolution of fever"],
    "optional": ["CBC if prolonged therapy"]
  },

  "drug_interactions": {
    "major": ["calcium-containing IV solutions (neonates)"],
    "moderate": []
  },

  "adverse_effects": {
    "common": ["diarrhea", "injection site reaction"],
    "serious": ["C. difficile colitis", "hypersensitivity reactions"],
    "rare": ["hemolytic anemia", "biliary sludging"]
  },

  "spectrum": {
    "gram_positive": "Good (except MRSA, Enterococcus)",
    "gram_negative": "Excellent (E. coli, Klebsiella, Proteus)",
    "anaerobes": "Limited (combine with metronidazole if needed)",
    "atypicals": "No coverage"
  },

  "notes": [
    "First-line for community-acquired pyelonephritis",
    "Once-daily dosing improves compliance",
    "No renal adjustment needed",
    "Safe in pregnancy",
    "Higher dose (2g q12h) for meningitis"
  ],

  "evidence": [
    "IDSA Complicated UTI Guidelines 2019",
    "IDSA Meningitis Guidelines 2017",
    "IDSA/ATS CAP Guidelines 2019"
  ]
}
